Minerva Neurosciences, Inc. (NERV) stock
NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.16−0.04 (-1.82%)
Close on Nov 17, 2026Market cap $103.14MP/E –Yield –
Minerva Neurosciences total assets
Total assets on the balance sheet at the end of each period.
Minerva Neurosciences's total assets was $95.09M at Jun 30, 2026. For fiscal 2025 it was $97.97M, up 163.8% from the year before. Over ten years it grew 1.7% a year on average. The highest annual figure on record is $183.70M in fiscal 2017.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.97M | +163.8% |
| FY2024 | Dec 31, 2024 | $37.14M | -34.7% |
| FY2023 | Dec 31, 2023 | $56.90M | +3.3% |
| FY2022 | Dec 31, 2022 | $55.09M | -28.6% |
| FY2021 | Dec 31, 2021 | $77.12M | +33.8% |
| FY2020 | Dec 31, 2020 | $57.63M | -25.6% |
| FY2019 | Dec 31, 2019 | $77.50M | -44.3% |
| FY2018 | Dec 31, 2018 | $139.14M | -24.3% |
| FY2017 | Dec 31, 2017 | $183.70M | +38.2% |
| FY2016 | Dec 31, 2016 | $132.94M | +61.0% |
| FY2015 | Dec 31, 2015 | $82.58M | +20.6% |
| FY2014 | Dec 31, 2014 | $68.45M | +134.6% |
| FY2013 | Dec 31, 2013 | $29.17M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $95.09M | +212.6% |
| Q1 FY2026 | Mar 31, 2026 | $94.03M | +186.7% |
| Q4 FY2025 | Dec 31, 2025 | $97.97M | +163.8% |
| Q3 FY2025 | Sep 30, 2025 | $28.09M | -34.4% |
| Q2 FY2025 | Jun 30, 2025 | $30.42M | -34.3% |
| Q1 FY2025 | Mar 31, 2025 | $32.80M | -35.1% |
| Q4 FY2024 | Dec 31, 2024 | $37.14M | -34.7% |
| Q3 FY2024 | Sep 30, 2024 | $42.81M | -32.2% |
| Q2 FY2024 | Jun 30, 2024 | $46.29M | -31.1% |
| Q1 FY2024 | Mar 31, 2024 | $50.51M | -2.1% |
| Q4 FY2023 | Dec 31, 2023 | $56.90M | +3.3% |
| Q3 FY2023 | Sep 30, 2023 | $63.13M | +5.6% |
| Q2 FY2023 | Jun 30, 2023 | $67.14M | +3.4% |
| Q1 FY2023 | Mar 31, 2023 | $51.59M | -26.9% |
| Q4 FY2022 | Dec 31, 2022 | $55.09M | -28.6% |
| Q3 FY2022 | Sep 30, 2022 | $59.76M | -38.7% |
| Q2 FY2022 | Jun 30, 2022 | $64.96M | -38.3% |
| Q1 FY2022 | Mar 31, 2022 | $70.62M | -36.9% |
| Q4 FY2021 | Dec 31, 2021 | $77.12M | +33.8% |
| Q3 FY2021 | Sep 30, 2021 | $97.56M | +49.6% |
| Q2 FY2021 | Jun 30, 2021 | $105.32M | +59.2% |
| Q1 FY2021 | Mar 31, 2021 | $111.83M | +62.6% |
| Q4 FY2020 | Dec 31, 2020 | $57.63M | -25.6% |
| Q3 FY2020 | Sep 30, 2020 | $65.22M | -41.1% |
| Q2 FY2020 | Jun 30, 2020 | $66.17M | -45.0% |
| Q1 FY2020 | Mar 31, 2020 | $68.79M | -47.0% |
| Q4 FY2019 | Dec 31, 2019 | $77.50M | -44.3% |
| Q3 FY2019 | Sep 30, 2019 | $110.81M | -26.4% |
| Q2 FY2019 | Jun 30, 2019 | $120.29M | -25.3% |
| Q1 FY2019 | Mar 31, 2019 | $129.80M | -25.6% |
| Q4 FY2018 | Dec 31, 2018 | $139.14M | -24.3% |
| Q3 FY2018 | Sep 30, 2018 | $150.53M | -22.2% |
| Q2 FY2018 | Jun 30, 2018 | $160.94M | +26.3% |
| Q1 FY2018 | Mar 31, 2018 | $174.47M | +28.9% |
| Q4 FY2017 | Dec 31, 2017 | $183.70M | +38.2% |
| Q3 FY2017 | Sep 30, 2017 | $193.51M | +36.5% |
| Q2 FY2017 | Jun 30, 2017 | $127.38M | – |
| Q1 FY2017 | Mar 31, 2017 | $135.31M | – |
| Q4 FY2016 | Dec 31, 2016 | $132.94M | – |
| Q3 FY2016 | Sep 30, 2016 | $141.72M | – |
See a number that looks wrong?